SLC transporters as therapeutic targets: emerging opportunities

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Nature reviews. Drug discovery

• Publication date

  2015-06-26

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nrd4626PMID 26111766PMCID PMC4698371
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Further information

  2018cited by this paper
• Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease

  2016cited by this paper
• Integrating the monoamine, neurotrophin and cytokine hypotheses of depression--a central role for the serotonin transporter?

  2015cited by this paper
• Pendred Syndrome/DFNB4

  2014cited by this paper
• The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication.

  2014cited by this paper
• Bitopertin: the good news and bad news.

  2014cited by this paper
• an update on

  2014cited by this paper
• Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo.

  2014cited by this paper
• The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse.

  2014cited by this paper
• Practical Considerations

  2014cited by this paper
• Glycine transport inhibitors for the treatment of pain.

  2014cited by this paper
• Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors.

  2014cited by this paper
• Snapshot of antidepressants at work: the structure of neurotransmitter transporter proteins.

  2014cited by this paper
• Loss-of-function mutations in SLC30A8 protect against type 2 diabetes

  2014cited by this paper
• Using Positron Emission Tomography to Study Transporter-Mediated Drug–Drug Interactions in Tissues

  2014cited by this paper
• Structural basis of nucleoside and nucleoside drug selectivity by concentrative nucleoside transporters

  2014cited by this paper
• In Vivo Detection of Monoaminergic Degeneration in Early Parkinson Disease by 18F-9-Fluoropropyl-(+)-Dihydrotetrabenzazine PET

  2014cited by this paper
• The Janus Kinase 2 Inhibitor Fedratinib Inhibits Thiamine Uptake: A Putative Mechanism for the Onset of Wernicke’s Encephalopathy

  2014cited by this paper
• Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone

  2014cited by this paper
• Genetic implication of a novel thiamine transporter in human hypertension.

  2014cited by this paper
• Canagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus

  2014cited by this paper
• In vitro methods in drug transporter interaction assessment.

  2014cited by this paper
• Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Synthesis, biological characterization, and development of a pharmacophore model.

  2014cited by this paper
• Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.

  2014cited by this paper
• Small-molecule activator of glutamate transporter EAAT2 translation provides neuroprotection.

  2014cited by this paper
• Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.

  2013cited by this paper
• X-ray structure of dopamine transporter elucidates antidepressant mechanism

  2013cited by this paper
• Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes.

  2013cited by this paper
• Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.

  2013cited by this paper
• The solute carrier family 10 (SLC10): beyond bile acid transport.

  2013cited by this paper
• New therapies for gout.

  2013cited by this paper
• Cystic fibrosis therapeutics: the road ahead.

  2013cited by this paper
• Early Identification of Clinically Relevant Drug Interactions With the Human Bile Salt Export Pump (BSEP/ABCB11)

  2013cited by this paper
• Physiology and pathophysiology

  2013cited by this paper
• Synthesis and biological evaluation of new creatine fatty esters revealed dodecyl creatine ester as a promising drug candidate for the treatment of the creatine transporter deficiency.

  2013cited by this paper
• Impact of genetic variation in OATP transporters to drug disposition and response.

  2013cited by this paper
• Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain

  2013cited by this paper
• The SLC3 and SLC7 families of amino acid transporters.

  2013cited by this paper
• Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer

  2013cited by this paper
• Physiology and pathophysiology of SLC12A1/2 transporters

  2013cited by this paper
• SLC Classification: An Update

  2013cited by this paper
• The ABCs of membrane transporters in health and disease (SLC series): Introduction

  2013cited by this paper
• Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets.

  2013cited by this paper
• Double-blind, randomized placebo-controlled clinical trial of benfotiamine for severe alcohol dependence.

  2013cited by this paper
• The SLC1 high-affinity glutamate and neutral amino acid transporter family.

  2013cited by this paper
• Hunting human disease genes: lessons from the past, challenges for the future

  2013cited by this paper
• Solute carriers (SLCs) in cancer.

  2013cited by this paper
• Genetics of Hyperuricemia and Gout: Implications for the Present and Future

  2013cited by this paper
• Riluzole increases glutamate uptake by cultured C6 astroglial cells

  2013cited by this paper
• Occupancy of serotonin and norepinephrine transporter by milnacipran in patients with major depressive disorder: a positron emission tomography study with [(11)C]DASB and (S,S)-[(18)F]FMeNER-D(2).

  2013cited by this paper
• Structure-based ligand discovery for the Large-neutral Amino Acid Transporter 1, LAT-1

  2013cited by this paper
• Study Design and Rationale of a Dose‐Ranging Trial of LX4211, a Dual Inhibitor of SGLT1 and SGLT2, in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy

  2013cited by this paper
• Monoamine Transporter Occupancy of a Novel Triple Reuptake Inhibitor in Baboons and Humans Using Positron Emission Tomography

  2013cited by this paper
• Chronic brain ischemia induces the expression of glial glutamate transporter EAAT2 in subcortical white matter.

  2013cited by this paper
• The diabetes-susceptible gene SLC30A8/ZnT8 regulates hepatic insulin clearance.

  2013cited by this paper
• Solute carriers as drug targets: current use, clinical trials and prospective.

  2013cited by this paper
• Chemical predictive modelling to improve compound quality

  2013cited by this paper
• Substrate-Dependent Inhibition of Organic Anion Transporting Polypeptide 1B1: Comparative Analysis with Prototypical Probe Substrates Estradiol-17β-Glucuronide, Estrone-3-Sulfate, and Sulfobromophthalein

  2013cited by this paper
• Nutrient transporters: the Achilles' heel of anabolism.

  2013cited by this paper
• The SLCO (former SLC21) superfamily of transporters.

  2013cited by this paper
• The synthesis and biodistribution of [(11)C]metformin as a PET probe to study hepatobiliary transport mediated by the multi-drug and toxin extrusion transporter 1 (MATE1) in vivo.

  2013cited by this paper
• Inside Out: Targeting NHE1 as an Intracellular and Extracellular Regulator of Cancer Progression

  2013cited by this paper
• New fluorescent substrate enables quantitative and high-throughput examination of vesicular monoamine transporter 2 (VMAT2).

  2013cited by this paper
• Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.

  2013cited by this paper
• Allosteric Modulation of an Excitatory Amino Acid Transporter: The Subtype-Selective Inhibitor UCPH-101 Exerts Sustained Inhibition of EAAT1 through an Intramonomeric Site in the Trimerization Domain

  2013cited by this paper
• A Genome‐Wide Association Study for Serum Bilirubin Levels and Gene‐Environment Interaction in a Chinese Population

  2013cited by this paper
• Hereditary conjugated hyperbilirubinaemia: 37 years later.

  2013cited by this paper
• Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.

  2013cited by this paper
• Glucose transport families SLC5 and SLC50.

  2013cited by this paper
• Molecular modeling and ligand docking for solute carrier (SLC) transporters.

  2013cited by this paper
• [18F]Fluorodeoxyglucose accumulation as a biological marker of hypoxic status but not glucose transport ability in gastric cancer

  2013cited by this paper
• The SLC2 (GLUT) family of membrane transporters.

  2013cited by this paper
• [18F]Fluorodeoxyglucose accumulation as a biological marker of hypoxic status but not glucose transport ability in gastric cancer

  2013cited by this paper
• SLC1A5 Mediates Glutamine Transport Required for Lung Cancer Cell Growth and Survival

  2012cited by this paper
• Pharmacological Estrogen Administration Causes a FSH-Independent Osteo-Anabolic Effect Requiring ER Alpha in Osteoblasts

  2012cited by this paper
• Amino Acid transporter-targeted radiotracers for molecular imaging in oncology.

  2012cited by this paper
• Inhibition of Intestinal Bile Acid Transporter Slc10a2 Improves Triglyceride Metabolism and Normalizes Elevated Plasma Glucose Levels in Mice

  2012cited by this paper
• Structural Exploration of (3S,6S)‐6‐Benzhydryl‐N‐benzyltetrahydro‐2H‐pyran‐3‐amine Analogues: Identification of Potent Triple Monoamine Reuptake Inhibitors as Potential Antidepressants

  2012cited by this paper
• Cyclocreatine treatment improves cognition in mice with creatine transporter deficiency.

  2012influential reference
• Crystal structure of a concentrative nucleoside transporter from Vibrio cholerae at 2.4 Å

  2012cited by this paper
• A role for the organic anion transporter OAT3 in renal creatinine secretion in mice.

  2012cited by this paper
• Genome-wide association analyses identify 18 new loci associated with serum urate concentrations

  2012cited by this paper
• A Small-Molecule Inhibitor of Glucose Transporter 1 Downregulates Glycolysis, Induces Cell-Cycle Arrest, and Inhibits Cancer Cell Growth In Vitro and In Vivo

  2012cited by this paper
• Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy

  2012cited by this paper
• NHE-1: a promising target for novel anti-cancer therapeutics.

  2012cited by this paper
• Glutamate transporter EAAT2: a new target for the treatment of neurodegenerative diseases.

  2012cited by this paper
• Glycine transporter type 2 (GlyT2) inhibitor ameliorates bladder overactivity and nociceptive behavior in rats.

  2012cited by this paper
• SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: a PET study

  2012cited by this paper
• Structure-activity relationship study of selective excitatory amino acid transporter subtype 1 (EAAT1) inhibitor 2-amino-4-(4-methoxyphenyl)-7-(naphthalen-1-yl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile (UCPH-101) and absolute configurational assignment using infrared and vibrational circu

  2012cited by this paper
• LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial

  2012cited by this paper
• New clinical perspectives of hypolipidemic drug therapy in severe hypercholesterolemia.

  2012cited by this paper
• Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver.

  2012cited by this paper
• KGA-2727, a Novel Selective Inhibitor of a High-Affinity Sodium Glucose Cotransporter (SGLT1), Exhibits Antidiabetic Efficacy in Rodent Models

  2012cited by this paper
• High Selectivity of the γ-Aminobutyric Acid Transporter 2 (GAT-2, SLC6A13) Revealed by Structure-based Approach*

  2012cited by this paper
• Riluzole elevates GLT-1 activity and levels in striatal astrocytes.

  2012cited by this paper
• Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1).

  2012cited by this paper
• In Vitro 2-Deoxy-2-[18F]Fluoro-D-Glucose Uptake: Practical Considerations

  2012cited by this paper
• A novel target for diuretic therapy.

  2012cited by this paper
• Na+-H+ exchanger, pH regulation and cancer.

  2012cited by this paper
• Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.

  2012cited by this paper

• Serine inhibits granulosa cell ferroptosis to maintain ovarian function

  2026cites this paper
• Binder2030: a quantitative membrane proteome binding dataset enabling AI-driven drug discovery.

  2026cites this paper
• Metabolic reprogramming of efferocytosis in the tumour microenvironment: From apoptotic‐cell clearance to therapeutic targeting

  2026cites this paper
• High-throughput ligand discovery in living cells using the cellular protein stability enhancement assay

  2026cites this paper
• The Solute Carrier (SLC) Transporter Superfamily as Therapeutic Targets for the Treatment of Ovarian Serous Cystadenocarcinoma.

  2026cites this paper
• Dual binding and efflux mechanisms involving HMOX2 and ABCB1 regulate the tumor selectivity of a near-infrared theranostic probe.

  2026cites this paper
• Target Class Repurposing Across Membrane Transporter Families Provides Privileged Ligands to Address Specific and Undruggable Pharmacological Targets.

  2026cites this paper
• Wuji Wan ameliorates ulcerative colitis by restoring impaired membrane transport

  2026cites this paper
• 16-h fasting optimizes cancer immunotherapy in mice and humans.

  2026cites this paper
• Genetic dissection of stool frequency implicates vitamin B1 metabolism and other actionable pathways in the modulation of gut motility

  2026cites this paper
• Molecular Targets for Cancer Immunotherapy: Focusing on (Immune and Tumor) Cell-Derived Metabolites

  2026cites this paper
• Applications of in vitro transporter assays for mechanistic characterization and prediction of clinical drug-drug interactions.

  2026cites this paper
• A Proteochemometric Model for Ligands of the SLC5 Transporter Family

  2026cites this paper
• Probing ligand-induced conformational changes in an MFS transporter in vivo using site-directed PEGylation.

  2025cites this paper
• Proteomic profiling reveals age-related changes in transporter proteins in the human blood–brain barrier

  2025cites this paper
• Structural pharmacology of SV2A reveals an allosteric modulation mechanism in the major facilitator superfamily

  2025cites this paper
• Quantifying VMAT2 target occupancy at effective valbenazine doses and comparing to a novel VMAT2 inhibitor: a translational PET study

  2025cites this paper
• Molecular and biophysical remodeling of the blood–brain barrier in glioblastoma: mechanistic drivers of tumor–neurovascular crosstalk

  2025cites this paper
• Diverse infections transcriptionally reprogram the intestinal epithelium and epithelial-immune cell interactions

  2025cites this paper
• Itaconate transport across the plasma membrane and Salmonella-containing vacuole via MCT1/4 modulates macrophage antibacterial activity

  2025cites this paper
• Identification of MFSD3 as a potential prognostic biomarker of cervical cancer

  2025cites this paper
• Allosteric modulation of the solute carrier transporter SLC39A8 potentiates manganese and cadmium uptake

  2025cites this paper
• Effects of SCT genetic polymorphisms on methotrexate concentrations and toxicities in Chinese children with acute lymphoblastic leukemia

  2025cites this paper
• Solute carrier protein family: physiological functions, disease associations, and therapeutic potential in immune-related disorders

  2025cites this paper
• Structural basis of aromatic amino acid recognition by the human ACE2-B 0AT1 transporter complex

  2025cites this paper
• Functional and structural polypharmacology of indazole-based privileged ligands to tackle the undruggability of membrane transporters.

  2025cites this paper
• Membrane drug transporters in cancer: From chemoresistance mechanism to therapeutic strategies.

  2025cites this paper
• Meme Kanserinde Glutamin Metabolizması ve Solüt Taşıyıcıların Terapötik Potansiyeli

  2025cites this paper
• Structure-activity relationship of isoprenoid triazole bisphosphonate-based geranylgeranyl diphosphate synthase inhibitors: Effects on pharmacokinetics, biodistribution, and hepatic transporters

  2025cites this paper
• SLC13A2 promotes hepatocyte metabolic remodeling and liver regeneration by enhancing de novo cholesterol biosynthesis

  2025cites this paper
• Inactivation mechanisms of Na+/HCO3− cotransporter NBCe1 by phosphorylation

  2025cites this paper
• Disulfidptosis mechanisms and therapeutic implications in cancer metabolic reprogramming and future perspectives

  2025cites this paper
• Chemically gated artificial nanochannels for programmable subcellular signal modulated transport regulation

  2025cites this paper
• Photocatalytic Microenvironment Proteomics of Thiol-Mediated Uptake

  2025cites this paper
• Selective Alanine Transporter Utilization is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer.

  2025cites this paper
• Comparative transcriptome analysis of juvenile greater amberjack (Seriola dumerili) revealed the molecular responses of the kidney to chronic salinity stress.

  2025cites this paper
• Cross-tissue coordination between SLC nucleoside transporters regulates reproduction in Caenorhabditis elegans

  2025cites this paper
• SLC1A5-dependent glutamine uptake in hepatocytes promotes liver regeneration

  2025cites this paper
• Recent advances in ASCT2 inhibitors: ligand design and therapeutic applications.

  2025cites this paper
• The SLCO4A1‐Mediated Transmembrane Transport of Lysionotin Attenuates Acute Lung Injury Through Activating the AMPK/Nrf2 Signaling Pathway

  2025cites this paper
• Fully-Functionalized Natural Product Probes to Expand the Chemical Tractability of the Human Proteome.

  2025cites this paper
• Slc7a7 licenses macrophage glutaminolysis for restorative functions in atherosclerosis

  2025cites this paper
• Combination of Drug Therapy and Membrane-Modified Exosomes for the Treatment of Rheumatoid Arthritis

  2025cites this paper
• Investigation of the gastric toxicity induced by exposure to tri-isobutyl phosphate.

  2025cites this paper
• The lncrnas: innovative multifunctional players of drug resistance in colorectal cancer

  2025cites this paper
• A new combined prognostic model involving SLC44A4 improves the predictive ability for colorectal cancer patients

  2025influential citation
• SLC1A4 Promotes Malignant Transformation of Hepatocellular Carcinoma by Activating the AKT Signaling

  2025cites this paper
• Molecular determinants of selective and high-affinity binding of the scaffold protein PDZK1 to the urate transporter URAT1.

  2025cites this paper
• A class of benzofuranoindoline-bearing heptacyclic fungal RiPPs with anticancer activities

  2025cites this paper
• Experimental and computational approaches for evaluating molecule interactions with equilibrative nucleoside transporters 1 and 2.

  2025cites this paper
• The Possibility of Plasma Membrane Transporters as Drug Targets in Oral Cancers

  2025cites this paper
• New insights into the role of solute carriers in response to salinity stress in the Manila clam (Ruditapes philippinarum).

  2025cites this paper
• The solute carrier superfamily interactome

  2025cites this paper
• Structural Dynamics of Neutral Amino Acid Transporter SLC6A19 in Simple and Complex Lipid Bilayers

  2025cites this paper
• Expression of SLC2A1 is upregulated in a mouse model of age-related hearing loss.

  2025cites this paper
• SLC4A7 suppresses lung adenocarcinoma oncogenesis by reducing lactate transport and protein lactylation

  2025cites this paper
• Understanding, inhibiting, and engineering membrane transporters with high-throughput mutational screens.

  2025cites this paper
• Whole-Genome Sequencing Identifies Functional Genes for Environmental Adaptability in Chinese Geese

  2025cites this paper
• Missense variants in SLC9A6 cause partial epilepsy without neurodevelopmental delay

  2025cites this paper
• Roles and Therapeutic Targeting of SLC Transporters in Gastrointestinal Malignancies.

  2025cites this paper
• The impact of solute carrier proteins on disrupting substance regulation in metabolic disorders: insights and clinical applications

  2025cites this paper
• A Review on the Role of Human Solute Carriers Transporters in Cancer

  2025cites this paper
• Targeting Frequent Efferocytosis in Tumor Microenvironment is a New Direction for Cancer Treatment

  2025cites this paper
• Solute carriers: The gatekeepers of metabolism.

  2025cites this paper
• Imagerie moléculaire pour l’étude des répercussions pharmacocinétiques des transporteurs hépatiques

  2025cites this paper
• Computational Approaches for Predicting Drug Interactions with Human Organic Anion Transporter 4 (OAT4).

  2025cites this paper
• The stomach, small intestine, and colon-specific gastrointestinal tract delivery systems for bioactive nutrients.

  2025cites this paper
• High-Intensity Interval Training Combined with Glycine Supplementation Drives Ferroptosis Resistance to Counteract Skeletal Muscle Atrophy in Aging Mice.

  2025cites this paper
• Artificial intelligence to predict inhibitors of drug-metabolizing enzymes and transporters for safer drug design

  2025cites this paper
• The Solute Carrier Superfamily as Therapeutic Targets in Pancreatic Ductal Adenocarcinoma

  2025cites this paper
• Influence of local ordering in the permeation of Temozolomide through the brain plasmatic membrane.

  2025cites this paper
• Crossing the Blood–Brain Barrier: Innovations in Receptor- and Transporter-Mediated Transcytosis Strategies

  2025cites this paper
• Breaking the Brain Barrier: Hybrid Nanoparticle-Enabled Delivery for Next-Gen Neurotherapeutics

  2025cites this paper
• Tunable NBD platform: high-performance fluorescent monitoring of cysteine fluctuations in ferroptosis.

  2025cites this paper
• Enhancing therapeutic strategies and drug development for patients with kidney disease

  2025cites this paper
• Ornithine Decarboxylase 1 and Solute Carrier Transporters: Coordinated gene expression in Response to glucotoxicity, an in vitro investigation.

  2025cites this paper
• Medical and Nonmedical Applications of Synthetic Transmembrane Anion Transporters

  2025cites this paper
• Mechanism and Structure-Guided Optimization of SLC1A1/EAAT3-Selective Inhibitors in Kidney Cancer

  2025cites this paper
• Influence of OCT2 gene variants on metformin efficacy in type 2 diabetes: insights into pharmacogenomics and drug interactions

  2025cites this paper
• Allosteric effects of the coupling cation in melibiose transporter MelB

  2025cites this paper
• Beyond the obvious: targeting the SLC transportome and non-canonical drug transport mechanisms in cancer therapy

  2025cites this paper
• Development of synthetic chloride transporters using high-throughput screening and machine learning

  2025cites this paper
• Epigenetic control of metabolic identity across cell types

  2025cites this paper
• Congenital Glucose–Galactose Malabsorption Presenting as Hypertriglyceridemia and Medullary Nephrocalcinosis

  2025cites this paper
• Single-nucleus transcriptome profiling of wild boar and domestic pig intestines reveals the spatiotemporal dynamics of immunity and nutrient absorption

  2025cites this paper
• Integrative multi-omics reveals that Salvia miltiorrhiza active fraction ameliorates rheumatoid arthritis in rats via inhibiting inflammation and ferroptosis.

  2025cites this paper
• Therapeutic potential of solute carrier transporters in cervical squamous cell carcinoma

  2025cites this paper
• URAT1 and GLUT9 as drug targets in gout: progress in transporter-directed therapies and delivery technologies

  2025cites this paper
• Gene library deep sequencing for protein super-family profiling

  2025cites this paper
• The role of m6A reader IGF2BPs in tumor metabolic reprogramming.

  2025cites this paper
• Single-cell RNA sequencing uncovers intestinal immune alterations and cellular diversity from chronic fluoride exposure in mice

  2025cites this paper
• S-adenosylmethionine and nicotinic acid suppress Hepatocellular carcinoma proliferation by targeting SLC25A4.

  2025cites this paper
• Unveiling the mechanisms and challenges of cancer drug resistance

  2024cites this paper
• Impact of 1α,25-dihydroxyvitamin D_3 on biodistribution and pharmacokinetics of L-carnitine and creatinine, organic cation/carnitine transporter 2 and organic cation transporter 2 biomarkers

  2024cites this paper
• The macrocycle inhibitor landscape of SLC‐transporter

  2024cites this paper
• Comprehensive review of amino acid transporters as therapeutic targets.

  2024cites this paper
• Computational Chemistry in Structure-Based Solute Carrier Transporter Drug Design: Recent Advances and Future Perspectives

  2024cites this paper
• In Silico prediction of inhibitors for multiple transporters via machine learning methods

  2024cites this paper
• Membrane transporters in drug development and as determinants of precision medicine

  2024cites this paper
• Changes in the Dentate Gyrus Gene Expression Profile Induced by Levetiracetam Treatment in Rats with Mesial Temporal Lobe Epilepsy

  2024cites this paper